

February 13, 2020

Listing Department  
**BSE LIMITED**

P J Towers, Dalal Street, Fort,  
Mumbai – 400 001

**Code: 532 321**

Listing Department

**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**

Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai – 400 051

**Code: CADILAHC**

**Re.:** Press Release

Dear Sir/Madam,

Please find enclosed a copy of press release dated February 13, 2020 titled “Zydus receives final approval from the USFDA for Mesalamine Suppositories for rectal use, 1000 mg”.


The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**

  
**DHAVAL N. SONI**  
**COMPANY SECRETARY**



**Encl.:** As above

## **Zydus receives final approval from the USFDA for Mesalamine Suppositories for rectal use, 1000 mg**

---

*Ahmedabad, 13 February, 2020*

Zydus Cadila has received the final approval from the USFDA to market Mesalamine Suppositories for rectal use, (US RLD - Canasa) 1000 mg. The drug is used to treat ulcerative proctitis, a type of bowel disease. It is an aminosalicylate anti-inflammatory drug and believed to work by blocking the production of certain natural chemicals that may cause pain and swelling. This will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

The group now has 280 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

### **About Zydus Cadila**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

\*\*\*